TCGA-90-7769-01A-11R-2125-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.550
- OXIDATIVE_PHOSPHORYLATION+0.470
- E2F_TARGETS+0.460
- MTORC1_SIGNALING+0.460
- G2M_CHECKPOINT+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.370
- CHOLESTEROL_HOMEOSTASIS+0.340
- P53_PATHWAY+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.440
- ANGIOGENESIS-0.340
- COMPLEMENT-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- COAGULATION-0.210
- KRAS_SIGNALING_UP-0.210
- INFLAMMATORY_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.927 |
| 2 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.911 |
| 3 | TCGA-22-5473-01A-01R-1635-07 | — | cohortSQ2 | 0.896 |
| 4 | SRR8392895 | — | cohortSQ2 | 0.893 |
| 5 | TCGA-77-7463-01A-11R-2045-07 | — | cohortSQ1 | 0.889 |
| 6 | TCGA-22-5485-01A-01R-1635-07 | — | cohortSQ2 | 0.889 |
| 7 | TCGA-18-5595-01A-01R-1635-07 | — | cohortSQ2 | 0.889 |
| 8 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.888 |
| 9 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.882 |
| 10 | C3N-02434 | — | cohortSQ2 | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |